Postmenopausal estrogen replacement therapy and risk of AD: A population-based study

Neurology

Volumn 52, Issue 5, 1999, Pages 965-970

  Waring, S C ^a,b   Rocca, W A ^a   Petersen, R C ^a   O'Brien, P C ^a   Tangalos, E G ^a   Kokmen, E ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN;

ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DOSE RESPONSE; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RISK; TOPICAL DRUG ADMINISTRATION;

EID: 0033596811     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.5.965     Document Type: Article

References (32)

1. Singh M, Huang FS, Meyer EM, Simpkins JW. Estrogen deprivation and replacement affects active avoidance learning in female Sprague-Dawley rats. Soc Neurosci Abstracts 1992;18: 1246. Abstract.
2. Singh M, Simpkins JW. The effect of estradiol deprivation and replacement on high affinity choline uptake in frontal cortex and hippocampus of female Sprague-Dawley rats. In: Proceedings of the 75th Annual Endocrine Society Meeting. Bethesda, MD: Endocrine Society 1993:366. Abstract.
3. Flicker C, Dean RL, Watkins DL, Fisher SK, Bartus RT. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat. Pharmacol Biochem Behav 1983;18:973-981.
4. Luine V, Park D, Joh T, Reis D, McEwen B. Immunochemical demonstration of increased choline acetyltransferase concentration in rat preoptic area after estradiol administration. Brain Res 1980;191:273-277.
5. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46:1580-1584.
6. Paganini-Hill A. Does estrogen replacement therapy protect against Alzheimer's disease? Osteoporosis Int 1997;(suppl 1): S12-S17.
7. Sherwin BB, Phillips S. Estrogen and cognitive functioning in surgically menopausal women. Ann NY Acad Sci 1990;592: 474-475.
8. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-495.
9. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991;78:991-995.
10. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and non-demented control subjects. Arch Neurol 1994;51:896-900.
11. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-432.
12. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517-1521.
13. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40: 1698-1707.
14. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol 1990;28:766-774.
15. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984;15:335-341.
16. Amaducci LA, Fratiglioni L, Rocca WA, et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology 1986;36:922-931.
17. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994;140:262-267.
18. Paganini-Hill A. Estrogen replacement therapy in the elderly. Zentralbl Gynakol 1996;118:255-261.
19. Kurland LT, Molgaard CA. The patient record in epidemiology. Sci Am 1981;245:54-63.
20. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-274.
21. Kokmen E, Beard CM, Offord KP, Kurland LT. Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975. Neurology 1989;39:773-776.
22. Kokmen E, Beard CM, O'Brien PC, Offord KP, Kurland LT. Is the incidence of dementing illness changing? A 25-year time trend study in Rochester, Minnesota (1960-1984). Neurology 1993;43:1887-1892.
23. Beard CM, Kokmen E, O Brien PC, Kurland LT. The prevalence of dementia is changing over time in Rochester, Minnesota. Neurology 1995;45:75-79.
24. Kokmen E, Beard CM, O Brien PC, Kurland LT. Epidemiology of dementia in Rochester, Minnesota. Mayo Clin Proc 1996;71:275-282.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987:103-107.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA World Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
27. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-637.
28. Breslow NE, Day NE. Statistical methods in cancer research: analysis of case control studies, vol. 1. Lyon, France: International Agency for Research on Cancer, 1980.
29. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140: 256-261.
30. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156: 2213-2217.
31. Macera CA, Sun RKP, Yeager KK, Brandes DA. Sensitivity and specificity of death certificate diagnoses for dementing illnesses, 1988-1990. J Am Geriatr Soc 1992;40:479-481.
32. Sackett DL. Bias in analytic research. J Chron Dis 1979;32: 51-63.